Capricor Therapeutics, Inc. 4LN2.F Stock
Capricor Therapeutics, Inc. Price Chart
Capricor Therapeutics, Inc. 4LN2.F Financial and Trading Overview
Capricor Therapeutics, Inc. stock price | 5.65 EUR |
Previous Close | 4.33 EUR |
Open | 4.31 EUR |
Bid | 4.31 EUR x N/A |
Ask | 4.48 EUR x N/A |
Day's Range | 4.31 - 4.31 EUR |
52 Week Range | 3.1 - 6.62 EUR |
Volume | 130 EUR |
Avg. Volume | 22 EUR |
Market Cap | 110.82M EUR |
Beta (5Y Monthly) | 4.02183 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.76 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.5 EUR |
4LN2.F Valuation Measures
Enterprise Value | 66.89M EUR |
Trailing P/E | N/A |
Forward P/E | -4.531579 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 20.010967 |
Price/Book (mrq) | 17.499998 |
Enterprise Value/Revenue | 12.079 |
Enterprise Value/EBITDA | -2.277 |
Trading Information
Capricor Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 4.02183 |
52-Week Change | 17.48% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.62 EUR |
52 Week Low | 3.1 EUR |
50-Day Moving Average | 3.84 EUR |
200-Day Moving Average | 4.38 EUR |
4LN2.F Share Statistics
Avg. Volume (3 month) | 22 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 25.27M |
Float | 24.75M |
Short Ratio | N/A |
% Held by Insiders | 2.74% |
% Held by Institutions | 10.90% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -542.60% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -31.62% |
Return on Equity (ttm) | -187.81% |
Income Statement
Revenue (ttm) | 5.54M EUR |
Revenue Per Share (ttm) | 0.22 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 1.75M EUR |
EBITDA | -29379816 EUR |
Net Income Avi to Common (ttm) | -28969704 EUR |
Diluted EPS (ttm) | -1.13 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 45.17M EUR |
Total Cash Per Share (mrq) | 1.79 EUR |
Total Debt (mrq) | 2.39M EUR |
Total Debt/Equity (mrq) | 38.56 EUR |
Current Ratio (mrq) | 1.255 |
Book Value Per Share (mrq) | 0.246 |
Cash Flow Statement
Operating Cash Flow (ttm) | -14919843 EUR |
Levered Free Cash Flow (ttm) | 6.78M EUR |
Profile of Capricor Therapeutics, Inc.
Country | Germany |
State | CA |
City | San Diego |
Address | 10865 Road to the Cure |
ZIP | 92121 |
Phone | (858) 727-1755 |
Website | https://www.capricor.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 74 |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Q&A For Capricor Therapeutics, Inc. Stock
What is a current 4LN2.F stock price?
Capricor Therapeutics, Inc. 4LN2.F stock price today per share is 5.65 EUR.
How to purchase Capricor Therapeutics, Inc. stock?
You can buy 4LN2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Capricor Therapeutics, Inc.?
The stock symbol or ticker of Capricor Therapeutics, Inc. is 4LN2.F.
Which industry does the Capricor Therapeutics, Inc. company belong to?
The Capricor Therapeutics, Inc. industry is Biotechnology.
How many shares does Capricor Therapeutics, Inc. have in circulation?
The max supply of Capricor Therapeutics, Inc. shares is 31.81M.
What is Capricor Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Capricor Therapeutics, Inc. PE Ratio is now.
What was Capricor Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Capricor Therapeutics, Inc. EPS is -0.76 EUR over the trailing 12 months.
Which sector does the Capricor Therapeutics, Inc. company belong to?
The Capricor Therapeutics, Inc. sector is Healthcare.